Myeloma

August 17, 2021
Doctor talking with patient

Now Enrolling: EAA171/OPTIMUM for Myeloma

This randomized phase III trial aims to determine if the addition of ixazomib to lenalidomide improves overall survival in patients with multiple myeloma
February 25, 2021
Patient and doctor talking in office

Trial Spotlight: Shaji Kumar on the EQUATE Study for Newly Diagnosed Multiple Myeloma

The randomized EAA181 phase III trial seeks to determine whether there is any survival benefit from adding a fourth drug to induction therapy—and if so, in which patients
December 14, 2020
Clipboard and laptop

Now Enrolling: ECOG-ACRIN Opened Five New Trials in October

The five phase III trials span different cancer types: prostate, leukemia, anal, lung, and myeloma
December 14, 2020
Bonnie Ky, MD headshot

ECOG-ACRIN Names University of Pennsylvania’s Bonnie Ky As Its Young Investigator of the Year

Already among the most influential thought leaders in cardio-oncology, Dr. Ky is the first in this field to receive the Group’s highest research distinction
June 10, 2020
Dr. O'Dwyer and Dr. Schnall

From the Co-Chairs, June 2020

Strong EA research presence at ASCO 2020; the horrific killing of George Floyd; health equity and diversity in the field of oncology; the need for EA to participate in changing a specifically anti-racist culture and increase diversity and inclusion